Gerard Linssen

Dr. Gerard Linssen

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 June 2016 in American Heart Journal
Verified
Journal Article
Closed access
LHLiefke C. van der Heijden
Liefke C. van der Heijden
MKMarlies M. Kok
Marlies M. Kok
PDPeter W. Danse
Peter W. Danse
ASAlexander R. Schramm
Alexander R. Schramm
MHMarc Hartmann
Marc Hartmann
CBClemens von Birgelen
Clemens von Birgelen

15 March 2022 in JMIR Human Factors
Verified
Journal Article
Open access
IKIris Ten Klooster
Iris Ten Klooster
JWJobke Wentzel
Jobke Wentzel
FSFloor Sieverink
Floor Sieverink
GLGerard Linssen
Gerard Linssen
RWRobin Wesselink
Robin Wesselink
JGJEWC van Gemert-Pijnen
JEWC van Gemert-Pijnen
Background: The full potential of eHealth technologies to support self-management and disease management for patients with chronic diseases is not being reached. A possible explanation for these lacking results is that during the development process, insufficient attention is paid to the needs, wishes, and context of the prospective end users. To overcome such issues, the user-centered design practice of creating personas is widely accepted to ensure the fit between a technology and the target group or end users throughout all phases of development. Objective: In this study, we integrate several approaches to persona development into the Persona Approach Twente to attain a more holistic and structured approach that aligns with the iterative process of eHealth development. Methods: In 3 steps, a secondary analysis was carried out on different parts of the data set using the Partitioning Around Medoids clustering method. First, we used health-related electronic patient record data only. Second, we added person-related data that were gathered through interviews and questionnaires. Third, we added log data. Results: In the first step, 2 clusters were found, with average silhouette widths of 0.12 and 0.27. In the second step, again 2 clusters were found, with average silhouette widths of 0.08 and 0.12. In the third step, 3 clusters were identified, with average silhouette widths of 0.09, 0.12, and 0.04. Conclusions: The Persona Approach Twente is applicable for mixed types of data and allows alignment of this user-centered design method to the iterative approach of eHealth development. A variety of characteristics can be used that stretches beyond (standardized) medical and demographic measurements. Challenges lie in data quality and fitness for (quantitative) clustering.

30 March 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JHJob J. Herrmann
Job J. Herrmann
HRHans-Peter Brunner-La Rocca
Hans-Peter Brunner-La Rocca
LBLisette E. H. J. M. Baltussen
Lisette E. H. J. M. Baltussen
FBFabienne Beckers-Wesche
Fabienne Beckers-Wesche
SBSebastiaan C. A. M. Bekkers
Sebastiaan C. A. M. Bekkers
RKRoland van Kimmenade
Roland van Kimmenade

8 November 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EPEline H. Ploumen
Eline H. Ploumen
TPTineke H. Pinxterhuis
Tineke H. Pinxterhuis
RBRosaly A. Buiten
Rosaly A. Buiten
PZPaolo Zocca
Paolo Zocca
PDPeter W. Danse
Peter W. Danse
CBClemens von Birgelen
Clemens von Birgelen
Background: In a previous trial, higher 5‐year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus‐eluting stents (SES). We assessed 5‐year safety and efficacy of all‐comers as well as patients with diabetes treated with SES or Synergy everolimus‐eluting stents (EES) versus durable polymer Resolute Integrity zotarolimus‐eluting stents (ZES). Methods and Results: The randomized BIO‐RESORT (Comparison of Biodegradable Polymer and Durable Polymer Drug‐Eluting Stents in an All Comers Population) trial enrolled 3514 all‐comer patients at 4 Dutch cardiac centers. Patients aged ≥18 years who required percutaneous coronary intervention were eligible. Participants were stratified for diabetes and randomized to treatment with SES, EES, or ZES (1:1:1). The main end point was target vessel failure (cardiac mortality, target vessel myocardial infarction, or target vessel revascularization). Five‐year follow‐up was available in 3183 of 3514 (90.6%) patients. The main end point target vessel failure occurred in 142 of 1169 (12.7%) patients treated with SES, 130 of 1172 (11.6%) treated with EES, versus 157 of 1173 (14.1%) treated with ZES (hazard ratio [HR], 0.89 [95% CI, 0.71–1.12], P log‐rank =0.31; and HR, 0.82 [95% CI, 0.65–1.04], P log‐rank =0.10, respectively). Individual components of target vessel failure showed no significant between‐stent difference. Very late definite stent thrombosis rates were low and similar (SES, 1.1%; EES, 0.6%; ZES, 0.9%). In patients with diabetes, target vessel failure did not differ significantly between stent‐groups (SES, 19.8%; EES, 19.2%; versus ZES, 21.1% [ P log‐rank =0.69 and P log‐rank =0.63]). Conclusions: Orsiro SES, Synergy EES, and Resolute Integrity ZES showed similar 5‐year outcomes of safety and efficacy, including mortality. A prespecified stent comparison in patients with diabetes also revealed no significant differences in 5‐year clinical outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01674803.

19 April 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ANAnna Norhammar
Anna Norhammar
JBJohan Bodegard
Johan Bodegard
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
HHHermann Haller
Hermann Haller
GLGerard Linssen
Gerard Linssen
CICaReMe Cardiorenal Investigators
CaReMe Cardiorenal Investigators
Aim: To examine how the development of cardiovascular and renal disease (CVRD) translates to hospital healthcare costs in individuals with type 2 diabetes (T2D) initially free from CVRD. Methods: Data were obtained from the digital healthcare systems of 12 nations using a prespecified protocol. A fixed country‐specific index date of 1 January was chosen to secure sufficient cohort disease history and maximal follow‐up, varying between each nation from 2006 to 2017. At index, all individuals were free from any diagnoses of CVRD (including heart failure [HF], chronic kidney disease [CKD], coronary ischaemic disease, stroke, myocardial infarction [MI], or peripheral artery disease [PAD]). Outcomes during follow‐up were hospital visits for CKD, HF, MI, stroke, and PAD. Hospital healthcare costs obtained from six countries, representing 68% of the total study population, were cumulatively summarized for CVRD events occurring during follow‐up. Results: In total, 1.2 million CVRD‐free individuals with T2D were identified and followed for 4.5 years (mean), that is, 4.9 million patient‐years. The proportion of individuals indexed before 2010 was 18% ( n = 207 137); 2010‐2015, 31% (361 175); and after 2015, 52% (609 095). Overall, 184 420 (15.7%) developed CVRD, of which cardiorenal disease was most frequently the first disease to develop (59.7%), consisting of 23.0% HF and 36.7% CKD, and more common than stroke (16.9%), MI (13.7%), and PAD (9.7%). The total cumulative cost for CVRD was US$1 billion, of which 59.0% was attributed to cardiorenal disease, 3‐, 5‐, and 6‐fold times greater than the costs for stroke, MI, and PAD, respectively. Conclusion: Across all nations, HF or CKD was the most frequent CVRD manifestation to develop in a low‐risk population with T2D, accounting for the highest proportion of hospital healthcare costs. These novel findings highlight the importance of cardiorenal awareness when planning healthcare.

10 May 2026 in Nature Medicine
Verified
Journal Article
Open access
DVD. J. van Veldhuisen
D. J. van Veldhuisen
MRMichiel Rienstra
Michiel Rienstra
AMA. Mosterd
A. Mosterd
MAM. Alings
M. Alings
AVA. A. Voors
A. A. Voors
PMPeter Van Der Meer
Peter Van Der Meer
Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less were randomized to low-dose digoxin or placebo, with a target serum digoxin concentration of 0.5-0.9 ng ml-1. The mean age of the participants was 72 ± 9 years, 28% were women and 29% had atrial fibrillation. The primary outcome was a composite of total worsening heart failure events, defined as total hospitalizations or total urgent hospital visits for worsening heart failure and cardiovascular mortality. Over a median follow-up of 36.5 months, 238 primary-outcome events occurred in 131 of 500 patients in the digoxin group, and 291 primary-outcome events in 152 of 501 patients occurred in the placebo group (rate ratio 0.81; 95% confidence interval (CI) 0.61-1.07, P = 0.133). The total number of worsening heart failure events was 155 and 203 in the digoxin and placebo groups, respectively (rate ratio 0.76, 95% CI 0.54-1.05) and cardiovascular mortality occurred in 83 patients (17%) and 88 (18%) in the digoxin and placebo groups, respectively (hazard ratio 0.93, 95% CI 0.69-1.26). Low-dose digoxin was generally well tolerated and safe, and results were similar between men and women. The results of this trial indicate that in patients with heart failure and reduced or mildly reduced ejection fraction, low-dose digoxin did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality. ClinicalTrials.gov registration: NCT03783429 .